AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
INmune Bio Stock Soars 19.56% on Clinical Trial Success
Generated by AI AgentAinvest Pre-Market Radar
Monday, Jul 28, 2025 5:38 am ET1min read
Aime SummaryINmune Bio's stock surged by 19.56% in pre-market trading on July 28, 2025, driven by positive developments in its clinical trials and upcoming presentations.
INmune Bio is set to present findings from its Phase 2 MINDFuL trial of XPro™ at the Alzheimer's Association International Conference. This trial focuses on early Alzheimer's Disease, and the results are highly anticipated by investors and the medical community alike. The presentation is scheduled for July 24, 2025, and is expected to provide valuable insights into the efficacy and safety of XPro™ in treating Alzheimer's Disease.
Additionally,
has been in the spotlight for its innovative approach to treating herpes, with a new monthly treatment showing promise in Phase 2 trials. This development has further bolstered investor confidence in the company's pipeline and its potential to bring groundbreaking therapies to market.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Getty Images (NYSE:GETY) surges 5.51% on renewed investor confidence
Jan.02 2026
Olaplex Holdings (NASDAQ: OLPX) shares plunged 7.59% on mixed analyst outlooks and shifting institutional positioning.
Jan.02 2026
The Real Brokerage shares surge 7.04% on Jan. 2 2026 driven by regulatory tailwinds and restructuring optimism
Jan.02 2026
Vanda Pharmaceuticals shares surged 25.46% on partnership and FDA Breakthrough Therapy Designation.
Jan.02 2026
Vanda Pharmaceuticals shares surge 25.46% on partnership and FDA breakthrough designation
Jan.02 2026
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet